Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Credit for photos: White HouseIn 1992, 44-year old Philly trial lawyer and breast cancer survivor, Fran Visco, took the stand before the Senate Labor, HHS, Education Appropriations Subcommittee, asserting a tone and stance previously unfamiliar in the world of cancer groups asking for funding before Congress.

January 10, 2025

Vol.51 No.01

By Claire Marie Porter

Clinical Roundup

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Elinzanetant meets all endpoints in phase III trial for vasomotor symptoms caused by breast cancer treatments

Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer, demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (also known as hot flashes) from baseline to week four and 12 compared to placebo.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Psychedelic drug therapy may address mental health concerns in people with cancer and addiction

One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests. A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Heart disease patients may face increased breast cancer risk, MD Anderson observational study finds

According to researchers from The University of Texas MD Anderson Cancer Center, patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease compared to those with early-stage cancer at diagnosis.

January 10, 2025

Vol.51 No.01

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

YOU MAY BE INTERESTED IN

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

Elinzanetant meets all endpoints in phase III trial for vasomotor symptoms caused by breast cancer treatments

Psychedelic drug therapy may address mental health concerns in people with cancer and addiction

Heart disease patients may face increased breast cancer risk, MD Anderson observational study finds

Renew today!

Subscriber content

Never miss an issue!

Login